LACOG 0213 - AUGMENT
A phase 3, double-blind randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus placebo in subjucts with relapsed/refractory indolent lymphoma.
To evaluate the efficacy (PFS) and safety of rituximab plus lenalidomide combination therapy in subjects with relapsed/refratory indolent lumphoma.
This is a phase 3 multicenter, double-blind, randomized study is designed to evaluate the efficacy and safety of rituximab plus lenalidomide versus rituximab plus placebo.
Sample size: 350
LACOG Study Coordinator: Phillip Scheinberg
Phone: 55 51 3384 5334